CINECA IRIS Institutional Research Information System

DE MERCANTI, STEFANIA FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.156
EU - Europa 2.139
AS - Asia 1.148
AF - Africa 78
OC - Oceania 35
SA - Sud America 35
Continente sconosciuto - Info sul continente non disponibili 11
Totale 7.602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.094
IT - Italia 584
CN - Cina 506
SG - Singapore 272
SE - Svezia 265
IE - Irlanda 259
FR - Francia 190
DE - Germania 167
FI - Finlandia 113
GB - Regno Unito 104
UA - Ucraina 103
VN - Vietnam 90
DK - Danimarca 85
AT - Austria 72
KR - Corea 59
CA - Canada 49
SN - Senegal 48
IN - India 41
JP - Giappone 39
ES - Italia 37
ID - Indonesia 31
BE - Belgio 28
AU - Australia 26
TR - Turchia 25
NL - Olanda 24
BR - Brasile 22
IR - Iran 22
PL - Polonia 22
IL - Israele 20
GR - Grecia 19
HK - Hong Kong 15
MX - Messico 12
EU - Europa 11
MU - Mauritius 11
RU - Federazione Russa 11
RO - Romania 10
CZ - Repubblica Ceca 9
NZ - Nuova Zelanda 9
PT - Portogallo 7
CO - Colombia 6
NG - Nigeria 6
TW - Taiwan 6
UZ - Uzbekistan 6
EG - Egitto 5
RS - Serbia 5
BG - Bulgaria 4
NO - Norvegia 4
CH - Svizzera 3
LB - Libano 3
MK - Macedonia 3
ZA - Sudafrica 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
CL - Cile 2
EC - Ecuador 2
HU - Ungheria 2
KZ - Kazakistan 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
PK - Pakistan 2
TN - Tunisia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
HR - Croazia 1
LT - Lituania 1
MD - Moldavia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 7.602
Salva come PNG Salva come JPEG
Città #
Chandler 621
Ann Arbor 354
Dublin 255
Beijing 254
Fremont 222
Santa Clara 210
Singapore 207
Ashburn 185
Fairfield 159
Torino 151
Houston 129
Nyköping 125
Wilmington 116
Villeurbanne 106
Jacksonville 100
Dearborn 94
Woodbridge 84
Medford 82
Cambridge 77
Princeton 76
Vienna 71
Dong Ket 70
Columbus 69
Turin 67
Milan 65
Redwood City 64
Seattle 63
Guangzhou 40
Boardman 37
New York 30
Jakarta 29
Boston 28
Pisa 25
Washington 22
Munich 21
Brussels 20
Toronto 20
Warsaw 18
Helsinki 15
San Diego 15
Los Angeles 14
Rome 14
Shanghai 14
Chengdu 13
Nanjing 13
Hangzhou 12
Dallas 11
Limoges 11
Norwalk 11
London 10
Tokyo 10
Duncan 9
Frankfurt am Main 8
Istanbul 8
Kunming 8
Mountain View 8
San Francisco 8
San Mateo 8
Zhengzhou 8
Hong Kong 7
Jinan 7
Madrid 7
Menlo Park 7
Moncalieri 7
Mumbai 7
Ottawa 7
Paris 7
Salt Lake City 7
Wuhan 7
Abuja 6
Chicago 6
Coventry 6
Dresden 6
Fuzhou 6
Hebei 6
Hefei 6
Portland 6
Tejupilco de Hidalgo 6
Alessandria 5
Beinasco 5
Belgrade 5
Düsseldorf 5
Heidelberg 5
Kozani 5
Nürnberg 5
Oulu 5
Vancouver 5
Venteuil 5
Brisbane 4
Campinas 4
Istrana 4
Jerusalem 4
Lagarto 4
Mifflinburg 4
Netanya 4
Oldenburg 4
Phoenix 4
Richmond Hill 4
Rivalta di Torino 4
Settimo Torinese 4
Totale 4.816
Salva come PNG Salva come JPEG
Nome #
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 624
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 390
Heterozygous deletion of KLHL1/ATX8OS at the SCA8 locus is unlikely associated with cerebellar impairment in humans 375
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 331
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 194
Heterozygous deletion of KLHL1/ATXN8OS at the SCA8 locus are likely not associated with cerebellar impairment in humans 188
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient 176
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 175
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 158
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 157
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 155
Natalizumab in Multiple Sclerosis: Long-Term Management 142
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 136
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 130
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 124
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 119
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 115
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question 112
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 109
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 106
ALS patients and caregivers communication preferences and information seeking behaviour 103
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 102
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 97
Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort 97
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 92
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 92
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 91
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 90
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 88
Prognostic influence of pre-morbid smoking habits, diabetes, arterial hypertension and vascular risk profile on phenotype and outcome of ALS patients: a population-based study. 87
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 86
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 86
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 85
Epigenetic therapy for Friedreich ataxia. 84
Digital therapeutics in neurology 83
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 81
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 81
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 81
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 78
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 77
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 77
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 77
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 76
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 76
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 76
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 75
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 74
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 73
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 72
Atypical presentation of superficial sclerosis successfully treated with iron chelation 71
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 71
A real-world study of Alemtuzumab in a cohort of Italian patients 71
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 69
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis 69
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-  68
Family functioning and multiple sclerosis: Study protocol of a multicentric italian project 67
Ultrasound-guided botulinum toxin-A for sialorrhea: a 2-year prospective study 65
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial 64
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial 62
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome 61
Friedreich's ataxia patients and caregivers information seeking behaviour 59
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series 59
Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b 56
Extended interval dosing of natalizumab: is efficacy preserved? 55
Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study 51
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 49
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 47
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 46
Spinal Cord Compression due to extramedullary hematopoiesis in a young patient affected by beta thalassemia 44
Role of Th22 expansion in multiple sclerosis disease activity 43
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience 43
PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE 41
Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study 39
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 32
Source of medical information and behavioral seeking patterns in patients affected with Friedreich’s ataxia and their caregivers: a survey study 18
EPIGENETIC THERAPY FOR FRIEDREICH’S ATAXIA: A PHASE 1, FIRST IN MAN, ASCENDING DOSE CROSSOVER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RG2833 (A HISTONE DEACETYLASE INHIBITOR) IN ADULTS WITH FRIEDREICH’S ATAXIA 7
A real‐world study of alemtuzumab in a cohort of Italian patients 4
Totale 7.884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.807
article - articoli 0
book - libri 0
conference - conferenze 11.629
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020583 0 0 0 0 0 123 91 69 73 99 59 69
2020/20211.017 78 70 55 120 86 79 70 51 114 61 90 143
2021/20221.152 50 42 36 74 48 89 89 65 73 120 261 205
2022/20231.643 137 164 51 196 146 377 103 107 167 63 82 50
2023/2024732 99 106 56 48 51 121 25 39 0 49 50 88
2024/2025829 42 74 88 171 404 50 0 0 0 0 0 0
Totale 7.884